Erratum: Early weight loss while on lorcaserin, diet, and exercise as a predictor of week 52 weight-loss outcomes (Obesity (2014) 22 (2137-2146)) doi: 10.1002/oby.20841;Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes

Obesity

Volumn 22, Issue 10, 2014, Pages 2137-2146

  Smith, Steven R ^a   O'Neil, Patrick M ^b   Astrup, Arne ^c   Finer, Nicholas ^d   Sanchez Kam, Matilde ^e   Fraher, Kyle ^e   Fain, Randi ^f   Shanahan, William R ^e  

^a FLORIDA HOSPITAL   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e ARENA PHARMACEUTICALS   (United States)

^f EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LORCASERIN; PLACEBO; ANTIOBESITY AGENT; BENZAZEPINE DERIVATIVE;

ADULT; ARTICLE; BACKACHE; BODY MASS; BODY WEIGHT; COMORBIDITY; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIET; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; EXERCISE; FATIGUE; FEMALE; GASTROENTERITIS; HEADACHE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCLE SPASM; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OROPHARYNX PAIN; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT REDUCTION; XEROSTOMIA; ADOLESCENT; AGED; AREA UNDER THE CURVE; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; LIFESTYLE; OUTCOME ASSESSMENT; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-OBESITY AGENTS; AREA UNDER CURVE; BENZAZEPINES; DIABETES MELLITUS, TYPE 2; DIET; EXERCISE; FEMALE; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; OBESITY; OUTCOME ASSESSMENT (HEALTH CARE); WEIGHT LOSS; YOUNG ADULT;

EID: 84907697527     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20947     Document Type: Erratum

References (31)

1. Phentermine hydrochloride prescribing information [DailyMed WWW document]. URL http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid5dbe7b8bf-e31e-43e2-98b7-465d4a895702. Accessed August 19, 2013.
2. Nicklas JM, Huskey KW, Davis RB, Wee CC. Successful weight loss among obese US adults. Am J Prev Med 2012;42:481-485.
3. Franz MJ, Van Wormer JJ, Crain AL, et al. Weight-loss outcomes: A systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc 2007;107:1755-1767.
4. Clinical guidelines on the identification, evaluation, treatment of overweight and obesity in adults - the evidence report. National Institutes of Health. Obes Res 1998;6(Suppl 2):51S-209S.
5. American Diabetes Association. Position statement: Standards of medical care in diabetes - 2013. Diabetes Care 2013;36(Suppl 1):S11-S66.
6. Lyznicki JM, Young DC, Riggs JA, Davis RM. Obesity: Assessment and management in primary care. Council on Scientific Affairs AMA. Am Fam Physician 2001;63:2185-2196.
7. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005;112:2735-2752.
8. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss: An update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease From the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006;113:898-918.
9. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
10. Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677-1686.
11. Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine. Endocr Pract 2013;18:642-648.
12. Anandacoomarasamy A, Leibman S, Smith G, et al. Weight loss in obese people has structure-modifying effects on medial but not on lateral knee articular cartilage. Ann Rheum Dis 2012;71:26-32.
13. Christensen R, Astrup A, Bliddal H. Weight loss: The treatment of choice for knee osteoarthritis? A randomized trial. Osteoarthritis Cartilage 2005;13:20-27.
14. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-588.
15. Kang JG, Park CY. Anti-obesity drugs: A review about their effects and safety. Diab Metab J 2012;36:13-25.
16. Li MF, Cheung BM. Rise and fall of anti-obesity drugs. World J Diabetes 2011;2:19-23.
17. O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technol Assess 2001;5:1-81.
18. Wadden TA, Foster GD, Wang J, et al. Clinical correlates of short- and long-term weight loss. Am J Clin Nutr 1992;56(Suppl 1):271S-274S.
19. Stotland SC, Larocque M. Early treatment response as a predictor of ongoing weight loss in obesity treatment. Br J Health Psychol 2005;10:601-614.
20. Handjieva-Darlenska T, Handjiev S, Larsen TM, et al. Initial weight loss on an 800-kcal diet as a predictor of weight loss success after 8 weeks: The Diogenes study. Eur J Clin Nutr 2010;64:994-999.
21. Rissanen A, Lean M, Rössner S, Segal KR, Sjöström L. Predictive value of early weight loss in obesity management with orlistat: An evidence-based assessment of prescribing guidelines. Int J Obes Relat Metab Disord 2003;27:103-109.
22. O'Neil P, Foster G, Billes S, et al. Early weight loss with naltrexone SR/bupropion SR combination therapy for obesity predicts long-term weight loss (Abstract). Obesity 2009;17:S109.
23. Finer N, Ryan DH, Renz CL, Hewkin AC. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. Diabetes Obes Metab 2006;8:206-213.
24. Belviq prescribing information [WWW document]. URL http://us.eisai.com/package-inserts/BelviqPI.pdf. Accessed Aug 2, 2013.
25. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363:245-256.
26. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: The BLOSSOM trial. J Clin Endocrinol Metab 2011;96:3067-3077.
27. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: The BLOOM-DM study. Obesity (Silver Spring) 2012;20:1426-1436.
28. Arena Pharmaceuticals, Inc. Lorcaserin hydrochloride briefing document for FDA Advisory Committee meeting [WWW document]. URL http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM303200.pdf. Accessed Oct 4, 2013.
29. Caterson ID, Finer N, Coutinho W, et al. Maintained intentional weight loss reduces cardiovascular outcomes: Results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab 2012;14:523-530.
30. James WPT, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363:905-917.
31. Elfhag K, Rössner S. Who succeeds in maintaining weight loss? A conceptual review of factors associated with weight loss maintenance and weight regain. Obes Rev 2005;6:67-85.